Franziska Wachter | Medical Services
Programs & Services
Languages
- English
- German
Franziska Wachter | Education
Medical School
Ludwig Maximilian University of Munich
2013, Bavaria, Germany
Graduate School
Ludwig Maximilian University of Munich
2014, Bavaria, Germany
Internship
Boston Combined Residency Program (BCRP)
2017, Boston, MA
Residency
Boston Combined Residency Program (BCRP)
2019, Boston, MA
Fellowship
Hematology and Oncology
Dana-Farber Cancer Institute/Boston Children's Hospital
2022, Boston, MA
Franziska Wachter | Certifications
- American Board of Pediatrics (General)
- American Board of Pediatrics (Hematology-Oncology)
Franziska Wachter | Professional History
Dr. Wachter is a physician-scientist committed to combining compassionate, leading-edge care of
malignancies with groundbreaking research in experimental therapeutics. She obtained my M.D. from Ludwig Maximilians University Munich, Germany and graduated summa cum laude from Irmela Jeremia’s laboratory, where I studied mechanisms of chemoresistance and the influence of p53 reactivation responses to the extrinsic apoptotic pathway agonist TRAIL. She then continued her training in Loren Walensky's laboratory, which focuses on interrogating BCL-2 family protein biology through the lens of structural and chemical biology. Dr. Wachter's particular areas of study comprised investigating inhibitory mechanisms of the pro-apoptotic effector protein BAX as well as identifying and characterizing BAX activators identified in a NMR-based fragment screen. She also validated the on-target mechanism of a p53 reactivating stapled peptide drug. Currently, she continues her postdoc scientific training in Eric Fischer’s laboratory co-mentored by Scott Armstrong and uses modern structural biology methods and biochemistry with the goal to structurally define aberrant transcription in myeloid children with high-risk myeloid malignancies.
Dr Wachter attends on the pediatric stem cell transplant service, and her clinical interest is to improve outcomes for pediatric patients with AML and MDS after stem cell transplant. Her clinical research efforts focus on the role of novel therapeutics in the treatment of high-risk acute myeloid leukemia, with a special focus on disease control prior to hematopoietic stem cell transplant (HCT) and maintenance treatment after HCT to reduce the risk of relapse.